Oncotalks hematology videos and news

ASCO

Interviews recorded at the American Society of Clinical Oncology congress

ASCO 2019 Dr. Shani Paluch

ASCO 2019 Dr. Shani Paluch

Dr. Shani Paluch from the Sheba Medical Center, Tel Hashomer is commenting on the abstract "Juric D. et al. Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.", which was presented at ASCO 2019 in ChicagoReference: J Clin Oncol 37, 2019 (suppl; abstr 1038)
ASCO , Lithuania , Albania
00:04:10
ASCO 2019 Nethanel Asher, MD

ASCO 2019 Nethanel Asher, MD

Nethanel Asher, MD from the Sheba Medical Center, Tel Hashomer is commenting on the abstract "Schadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO).", which was presented at ASCO 2019 in ChicagoReference: J Clin Oncol 37, 2019 (suppl; abstr 9582)
ASCO , Lithuania , Hungary , Albania
00:03:42
ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

ASCO 2019 Prof. Piotr Rutkowski, MD, PhD

Prof. Piotr Rutkowski, MD, PhD from the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw is commenting on the abstract: "Nathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507", which was presented at ASCO 2019 in Chicago
ASCO , Lithuania , Hungary , Albania
00:06:31
ASCO 2019 Dr. Razvan Curca

ASCO 2019 Dr. Razvan Curca

Dr. Razvan Curca from the Spitalul Judetean de Urgenta, Alba Iulia is commenting on two publications presented at ASCO 2019 in ChicagoNathan P.D. et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. J Clin Oncol 37, 2019 (suppl; abstr 9507)Schadendorf D. et al. Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) + trametinib (T) or placebo (PBO). J Clin Oncol 37, 2019 (suppl; abstr 9582)TAF-ADV-2-06.2019
ASCO , Lithuania , Hungary , Albania
00:08:53
  • «
  • 1
  • 2

This website intends to use cookies to improve the site and your experience. By continuing to browse the site you are agreeing to accept our use of cookies . If you require further information and/or do not wish to have cookies placed when using the site, visit Privacy Notice.

On acceptance: use all cookie settings
On denial: use only necessary cookies